OTLKOTLK
Buy moreBuy more at today's $0.45, already under our buy price.
- 4 to watch· Below 50-day
$0.45−0.03 (−7.07%)
Price at 3:03 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETHealthcare · Very small company
The price we'd buy OTLK at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- Analysts' forecast on the Nasdaq earnings calendar
- Yahoo Finance daily closes to Nov 10
Any one could move it to Keep
Next report · Dec 18
over$0.08
loss per share
Compared with the S&P 500
16 points
worse in one day
36 points
worse in five trading days
−64.5% in a yearsince Nov 10, 2025
The news behind our call
written Oct 22, 10:33 AM ETOct 22, 10:33 AM ET · 2 articles · 2 sources
- Outlook Therapeutics received FDA approval for its wet age-related macular degeneration drug.
The scorecard shows strong expected earnings growth.
What changed
From Simply Wall Street and Stocktwits
Dec 18
in 36 days
OTLK reports earnings
Analysts expect $-0.08 a share.
Overview
In plain numbers
- Revenue fell 182% between FY 2025 and the last twelve months, to -$1.2M.
- It loses $47.44 on every revenue dollar at the operating line.
- It burned $56.1M of free cash in the last twelve months.
- It owes $18.4M and holds $11.2M in cash and investments, so net debt is $7.2M.
Key figures
- Revenue (TTM)
- −$1.2M
- Net income
- −$61.1M
- EPS (diluted)
- −$0.75
- Return on capital
- -1253.8%
- Current ratio
- 0.81
- Buyback yield
- -182.49%
Key facts
- Company value
- $106M
- Today's range
- 0.440.48
- Past year's range
- 0.202.47
- Yesterday's close
- $0.48
- Swings vs the market
- 0.8×smaller
- Next earnings
- Dec 18in 36 days